human | Q5 |
P735 | given name | Peter | Q2793400 |
Peter | Q2793400 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | male | Q6581097 |
Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
Q30315970 | 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts |
Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
Q36021406 | 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium |
Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
Q90622495 | A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) |
Q92609057 | A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial |
Q40486932 | A Standard Mammography Unit - Standard 3D Ultrasound Probe Fusion Prototype: First Results |
Q59355837 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk |
Q35755874 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer |
Q35957063 | A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density |
Q33747778 | A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. |
Q29417084 | A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. |
Q53650107 | A hybrid method towards automated nipple detection in 3D breast ultrasound images. |
Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
Q36435849 | A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. |
Q45251774 | A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer |
Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
Q24626194 | A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer |
Q90802186 | A randomized, window of opportunity study comparing the effects of the novel oral SERD AZD9496 with fulvestrant in patients with ER+ HER2- primary breast cancer |
Q57305942 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer |
Q33947899 | ABCA transporter gene expression and poor outcome in epithelial ovarian cancer |
Q37227494 | ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas |
Q60043872 | ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro |
Q35432936 | AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection |
Q61948755 | Abstract 3266: Expression quantitative trait locus analysis of triple negative breast cancer |
Q62583469 | Abstract 5488: Utilizing a pathway based analysis of genome wide association data to identify biomarkers of toxicity in breast cancer patients |
Q47347187 | Accuracy of radiological tumour size assessment and the risk for re-excision in a cohort of primary breast cancer patients |
Q57072034 | Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma |
Q58695244 | Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria |
Q38406780 | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study |
Q52647897 | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. |
Q36295107 | Advances in Breast Cancer - Looking Back over the Year |
Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
Q39432829 | Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001. |
Q64231027 | An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study |
Q36073563 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression |
Q42371458 | Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci |
Q64101095 | Analysis of GDF15 and IGFBP7 in Hyperemesis Gravidarum Support Causality |
Q36831854 | Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome |
Q89881422 | Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor α |
Q38667762 | Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study |
Q61451341 | Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 |
Q62774772 | Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 |
Q34138371 | Are Certified Breast Centers Cost-Effective? |
Q35142156 | Aspects of molecular diagnostics and therapy in obstetrics and gynecology |
Q34613673 | Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study |
Q30276986 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes |
Q46687084 | Assessment of breast cancer tumor size depends on method, histopathology and tumor size itself*. |
Q47399153 | Assessment of breast cancer tumour size using six different methods |
Q35156876 | Assessment of hepatocyte growth factor in ovarian cancer mortality |
Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
Q37684409 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer |
Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
Q35006860 | Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen |
Q33828680 | Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival |
Q24619808 | Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies |
Q40075679 | Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis |
Q39388382 | Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial |
Q37292963 | Association of ESR1 gene tagging SNPs with breast cancer risk |
Q99417214 | Association of Pathological Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-analysis |
Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
Q96680596 | Association of genomic variants at the Human Leukocyte Antigen locus with cervical cancer risk, HPV status, and gene expression |
Q114182713 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment |
Q53650262 | Association of mammographic density with hormone receptors in invasive breast cancers: results from a case-only study. |
Q44287591 | Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer |
Q41706112 | Association of molecular subtypes with breast cancer risk factors: a case-only analysis |
Q56337548 | Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study |
Q39423088 | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study |
Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
Q33812789 | Attention, cognitive control and motivation in ADHD: Linking event-related brain potentials and DNA methylation patterns in boys at early school age. |
Q57990746 | BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients |
Q56968709 | BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study |
Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
Q36295142 | Biomarkers in Breast Cancer - An Update |
Q35054455 | Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network |
Q33997918 | Biomarkers in women's cancers, gynecology, and obstetrics |
Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
Q34209663 | Breast Cancer 2012 - New Aspects |
Q37660589 | Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis |
Q34201805 | Breast Cancer Risk - Genes, Environment and Clinics |
Q35180940 | Breast Cancer Update 2014 - Focus on the Patient and the Tumour |
Q57148656 | Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS) |
Q50033721 | Breast cancer in young women: do BRCA1 or BRCA2 mutations matter? |
Q43122429 | Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial |
Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
Q39978884 | Breast volumetry using a three-dimensional surface assessment technique |
Q52849107 | CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients. |
Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
Q36419325 | CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer |
Q34793437 | CYP2B6*6 is associated with increased breast cancer risk |
Q37524058 | CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations |
Q33591915 | CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification |
Q28385765 | Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk |
Q43121689 | Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study |
Q53172588 | Changes in satisfaction in patients with gynaecological and breast malignancies: an analysis with the Socio-Economic Satisfaction and Quality of Life questionnaire. |
Q54196115 | Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. |
Q100392948 | Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases |
Q36245595 | Characterizing mammographic images by using generic texture features |
Q57098750 | Children of Prenatally Depressed Mothers: Externalizing and Internalizing Symptoms are Accompanied by Reductions in Specific Social-Emotional Competencies |
Q37858099 | Chlamydia trachomatis infection as a risk factor for infertility among women in Ghana, West Africa. |
Q47150180 | Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer? |
Q34221705 | Circulating miR-148b and miR-133a as biomarkers for breast cancer detection |
Q21134914 | Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection |
Q33958981 | Circulating tumor cells predict survival in early average-to-high risk breast cancer patients |
Q35782435 | Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer |
Q45746480 | Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity |
Q94486442 | Combined associations of a polygenic risk score and classical risk factors with breast cancer risk |
Q35668946 | Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk |
Q36490507 | Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). |
Q34126314 | Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer |
Q35891162 | Common breast cancer susceptibility loci are associated with triple-negative breast cancer |
Q36600605 | Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk |
Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
Q29417145 | Common variants at 19p13 are associated with susceptibility to ovarian cancer |
Q36255665 | Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer |
Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
Q35054469 | Comparison of Sonography versus Digital Breast Tomosynthesis to Locate Intramammary Marker Clips |
Q62583467 | Competitive analysis of pregnancy associated HLA-proteins in trophoblast and breast cancer tissue |
Q36026731 | Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer |
Q39256294 | Comprehensive visualization of paresthesia in breast cancer survivors |
Q31107007 | Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients |
Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
Q34342248 | Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk |
Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
Q46494349 | Correlates of the desire for improved cosmetic results after breast-conserving therapy and mastectomy in breast cancer patients |
Q37855560 | Correlation of high-risk human papilloma viruses but not of herpes viruses or Chlamydia trachomatis with endometriosis lesions |
Q37452184 | Correlation of histological and macroscopic findings in peritoneal endometriosis |
Q33775316 | Correlation of mammographic density and serum calcium levels in patients with primary breast cancer |
Q34278775 | Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System |
Q101216461 | Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers |
Q36540420 | DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer |
Q37685729 | DNA mismatch repair gene MSH6 implicated in determining age at natural menopause |
Q54516956 | Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. |
Q48635565 | Delivery mode and the course of pre- and postpartum depression. |
Q36069885 | Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial |
Q35624654 | Development and Validation of a Standardized Questionnaire and Standardized Diary for Use in Integrative Medicine Consultations in Gynecologic Oncology |
Q96590073 | Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) |
Q64982162 | Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. |
Q64980662 | Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice. |
Q47952423 | Did you drink alcohol during pregnancy? Inaccuracy and discontinuity of women's self-reports: On the way to establish meconium ethyl glucuronide (EtG) as a biomarker for alcohol consumption during pregnancy |
Q50868171 | Digit ratio (2D:4D) and behavioral symptoms in primary-school aged boys. |
Q41506407 | Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation |
Q43924266 | Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. |
Q39936321 | Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen |
Q47273243 | Effects of prenatal alcohol consumption on cognitive development and ADHD-related behaviour in primary-school age: a multilevel study based on meconium ethyl glucuronide |
Q40273075 | Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery. |
Q56967384 | Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer etc. |
Q57461653 | Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis |
Q22250928 | Einfluss des mütterlichen Alkoholkonsums während der Schwangerschaft auf die Entwicklung von ADHS beim Kind |
Q38636290 | Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients. |
Q54953677 | Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. |
Q52681182 | Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. |
Q35815412 | Endometriosis as a risk factor for ovarian or endometrial cancer - results of a hospital-based case-control study |
Q38720533 | Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci |
Q24633316 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer |
Q36487146 | Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk |
Q42649791 | Erratum to: The integrative epigenomic-transcriptomic landscape of ER positive breast cancer |
Q57319395 | Erratum: Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer |
Q57202568 | Erratum: Corrigendum: Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk |
Q33932856 | Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium |
Q36966218 | Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study |
Q37389684 | Evaluation of Newly Adapted Clip Marker System in Ultrasound-Guided Core Needle Biopsy for Suspicion of Breast Cancer |
Q34764981 | Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study |
Q37709871 | Evaluation of a Marker Clip System in Sonographically Guided Core Needle Biopsy for Breast Cancer Localization Before and After Neoadjuvant Chemotherapy |
Q43697261 | Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. |
Q47130842 | Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer |
Q91265555 | Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
Q35653910 | Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk |
Q34687073 | Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study |
Q36720821 | Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors |
Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
Q37631322 | Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma |
Q52872813 | Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. |
Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
Q30313653 | Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
Q45006117 | Factors influencing breast changes after pregnancy |
Q31150676 | FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients |
Q49796329 | Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. |
Q50748345 | Financial viability of perinatal centers in the longer term, taking legislative requirements into account. An examination of the cost-revenue structure of a Level I perinatal center. |
Q44318881 | Financing of certified centers: a willingness-to-pay analysis |
Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
Q35063160 | Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk |
Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
Q37002930 | Five endometrial cancer risk loci identified through genome-wide association analysis |
Q34979715 | Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium |
Q36295117 | Full Field Digital Mammography (FFDM) versus CMOS Technology versus Tomosynthesis (DBT) - Which System Increases the Quality of Intraoperative Imaging? |
Q37395450 | Full Field Digital Mammography (FFDM) versus CMOS Technology, Specimen Radiography System (SRS) and Tomosynthesis (DBT) - Which System Can Optimise Surgical Therapy? |
Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
Q36956156 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer |
Q55037331 | Galactography with Tomosynthesis Technique (Galactomosynthesis) - Renaissance of a Method? |
Q100426680 | Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients |
Q48361014 | Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. |
Q40137431 | Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium |
Q41040904 | Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study |
Q62583319 | Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk |
Q37389405 | Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer |
Q115209620 | Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus |
Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
Q54940815 | Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. |
Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
Q45968079 | Genetic risk factors for ovarian cancer and their role for endometriosis risk. |
Q46721561 | Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study |
Q37679549 | Genetic variants in the genes of the stress hormone signalling pathway and depressive symptoms during and after pregnancy |
Q48657862 | Genetic variants in the tryptophan hydroxylase 2 gene (TPH2) and depression during and after pregnancy. |
Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
Q36218993 | Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium |
Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
Q29417100 | Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer |
Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
Q29417135 | Genome-wide association study identifies a common variant associated with risk of endometrial cancer |
Q36024614 | Genome-wide association study identifies a possible susceptibility locus for endometrial cancer |
Q35061252 | Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk |
Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
Q33778612 | Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. |
Q59566871 | Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility |
Q38823212 | Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk |
Q38373098 | Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial |
Q88693944 | Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab |
Q36916243 | Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer |
Q45733546 | Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women |
Q40090312 | Grating-based darkfield imaging of human breast tissue |
Q36903047 | HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer |
Q46188099 | HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics |
Q99728010 | HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment |
Q26996601 | Health Services Research and Health Economy - Quality Care Training in Gynaecology, with Focus On Gynaecological Oncology |
Q48086218 | Health utilities in gynecological oncology and mastology in Germany |
Q37341647 | Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients |
Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
Q36311502 | Hereditary breast and ovarian cancer: review and future perspectives |
Q101570878 | Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany |
Q54566127 | Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. |
Q40060927 | History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium |
Q35815464 | Hormone Therapy and its Effect on the Prognosis in Breast Cancer Patients |
Q43694432 | Hormone replacement therapy and prognosis in ovarian cancer patients |
Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
Q37006170 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. |
Q30252854 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer |
Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
Q112717190 | Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer |
Q59291228 | Identification of a genetic variant associated with treatment outcome in ovarian cancer: the potential role of cholesterol metabolism as a determinant of response to chemotherapy |
Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
Q34038964 | Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions |
Q57170142 | Identification of nine new susceptibility loci for endometrial cancer |
Q36014067 | Identification of novel genetic markers of breast cancer survival |
Q35541663 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer |
Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
Q50866974 | Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. |
Q38606464 | Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry |
Q114184688 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model |
Q48122440 | Infarction of primary sensorimotor cortex impairs pain perception |
Q47318223 | Influence of mammographic density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics |
Q50089754 | Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. |
Q92942975 | Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study |
Q52572827 | Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. |
Q34996647 | Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer |
Q37684424 | Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration |
Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
Q35133135 | Inhibition of adhesion, proliferation, and invasion of primary endometriosis and endometrial stromal and ovarian carcinoma cells by a nonhyaluronan adhesion barrier gel. |
Q39775283 | Inhibition of hyperalgesia by conditioning electrical stimulation in a human pain model |
Q41012013 | Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). |
Q62774275 | Insulintherapie bei Diabetes mellitus |
Q62774815 | Insulintherapie bei Diabetes mellitus |
Q52857952 | Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. |
Q33390705 | Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial |
Q58124814 | Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Brea |
Q39390636 | Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study |
Q35576242 | Invasive Breast Cancer: Recognition of Molecular Subtypes |
Q34898735 | Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors |
Q64279327 | Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk |
Q47190168 | Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium |
Q44303312 | Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients |
Q44258071 | Ki67 measured after neoadjuvant chemotherapy for primary breast cancer |
Q34074094 | Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment |
Q35745601 | Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases |
Q52890142 | Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. |
Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
Q37725393 | Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome |
Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
Q46671490 | Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report |
Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
Q51057785 | Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit. |
Q125948696 | MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients |
Q45381957 | Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw. |
Q37382835 | Mammographic Density and Prediction of Nodal Status in Breast Cancer Patients |
Q39622978 | Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography |
Q37700515 | Meconium indicators of maternal alcohol abuse during pregnancy and association with patient characteristics |
Q114182490 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk |
Q98772941 | Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer |
Q36333368 | Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. |
Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
Q61446881 | Mindfulness-based Stress Reduction in Pregnancy: an App-Based Programme to Improve the Health of Mothers and Children (MINDFUL/PMI Study) |
Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
Q37798407 | Mitomycin C in patients with gynecological malignancies |
Q113695636 | Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setti |
Q34542660 | Molecular profiling of single circulating tumor cells with diagnostic intention |
Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
Q93064583 | Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial |
Q52675313 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. |
Q42363504 | Neoadjuvant Treatment of Breast Cancer - Advances and Limitations |
Q53752984 | Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). |
Q33415041 | Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial |
Q54534083 | Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. |
Q46634705 | Neoadjuvant chemotherapy in breast cancer: which diagnostic procedures can be used? |
Q33406730 | Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). |
Q43121691 | Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study |
Q26799669 | Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk |
Q53254794 | New diagnostic criteria in real-time elastography for the assessment of breast lesions. |
Q30275832 | No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival |
Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
Q37079859 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing |
Q35752042 | Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures |
Q36027025 | Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium |
Q39007087 | Optimizing R with SparkR on a commodity cluster for biomedical research |
Q52805657 | Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. |
Q48030360 | Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials |
Q31108673 | Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis |
Q39827385 | Oxytocin receptor DNA methylation in postpartum depression |
Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
Q47143943 | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. |
Q52874022 | PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. |
Q100312898 | PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer |
Q36184231 | PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. |
Q52897434 | PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primar |
Q52897474 | PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin |
Q33488582 | Pain perception and detailed visual pain mapping in breast cancer survivors |
Q34289136 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche |
Q52893849 | Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. |
Q38188183 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis |
Q112572520 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes |
Q52723445 | Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. |
Q37307937 | Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium |
Q39285061 | Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications |
Q51121776 | Patients' attitudes to totally implantable venous access port systems for gynecological or breast malignancies. |
Q34209634 | Percent Mammographic Density and Dense Area as Risk Factors for Breast Cancer |
Q46757183 | Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer |
Q34209656 | Pilot Study on the Detection of Simulated Lesions Using a 2D and 3D Digital Full-Field Mammography System with a Newly Developed High Resolution Detector Based on Two Shifts of a-Se |
Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
Q42985583 | Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy |
Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
Q46158039 | Polymorphisms in estrogen metabolism and estrogen pathway genes and the risk of miscarriage |
Q36915870 | Polymorphisms in inflammation pathway genes and endometrial cancer risk |
Q42013702 | Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients |
Q34767999 | Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy |
Q40142509 | Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer |
Q36966258 | Population distribution of lifetime risk of ovarian cancer in the United States |
Q41011976 | Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods |
Q92055460 | Prediction and clinical utility of a contralateral breast cancer risk model |
Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
Q58101133 | Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer |
Q36299086 | Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial |
Q92551866 | Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients |
Q47755445 | Prenatal and adult androgen activities in alcohol dependence |
Q57476250 | Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis |
Q38964883 | Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer |
Q30316383 | Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). |
Q92346464 | Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer |
Q36924426 | Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study |
Q42512310 | Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients |
Q45756790 | Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis |
Q45408422 | Prognostic significance of serum antibodies to HPV-16 L1 virus-like particles in patients with invasive cervical cancer |
Q45393694 | Prognostic significance of the detection of human papilloma virus L1 protein in smears of mild to moderate cervical intraepithelial lesions |
Q100746843 | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab |
Q54574341 | Proliferation and cell-cell fusion of endometrial carcinoma are induced by the human endogenous retroviral Syncytin-1 and regulated by TGF-beta. |
Q36903459 | Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening |
Q35608684 | Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer |
Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
Q90242034 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers |
Q43927056 | Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients |
Q43166541 | Quantification of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in meconium from newborns for detection of alcohol abuse in a maternal health evaluation study |
Q36009422 | RAD51B in Familial Breast Cancer |
Q90547034 | RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women |
Q47999353 | Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). |
Q35576256 | Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy |
Q98158747 | Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses |
Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
Q26830250 | Relevance of health economics in breast cancer treatment - the view of certified breast centres and their patients |
Q42236299 | Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. |
Q36799061 | Replication of Epigenetic Postpartum Depression Biomarkers and Variation with Hormone Levels |
Q45951126 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. |
Q48070774 | Response to "screening depression during and after pregnancy using the EPDS". |
Q34201814 | Risk Factors for Endometriosis in a German Case-Control Study |
Q36771007 | Risk and risk assessment for breast cancer: molecular and clinical aspects |
Q37300024 | Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. |
Q37624504 | Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10 |
Q54950358 | Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. |
Q37453871 | Role of genetic polymorphisms and ovarian cancer susceptibility |
Q36545934 | SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival |
Q55013059 | Saliva samples as a source of DNA for high throughput genotyping: an acceptable and sufficient means in improvement of risk estimation throughout mammographic diagnostics. |
Q64328965 | Self-reported Improvement in Side Effects and Quality of Life With Integrative Medicine in Breast Cancer Patients |
Q36320573 | Semi-automated De-identification of German Content Sensitive Reports for Big Data Analytics |
Q39102961 | Semi-automated delineation of breast cancer tumors and subsequent materialization using three-dimensional printing (rapid prototyping). |
Q42599064 | Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors |
Q36089391 | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer |
Q61118451 | Shared heritability and functional enrichment across six solid cancers |
Q64004349 | Shared heritability and functional enrichment across six solid cancers |
Q54547212 | Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. |
Q44470032 | Single nucleotide polymorphisms in the progesterone receptor gene and association with uterine leiomyoma tumor characteristics and disease risk |
Q44192343 | Socioeconomic status and depression during and after pregnancy in the Franconian Maternal Health Evaluation Studies (FRAMES). |
Q40386096 | Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group |
Q64273100 | Standards Used by a Clinical and Scientific Endometriosis Center for the Diagnosis and Therapy of Patients with Endometriosis |
Q59335365 | Supportive Infusions in Integrative Breast and Gynecological Oncology – Report on Patientsʼ Satisfaction and Self-reported Effects and Side Effects |
Q52807512 | Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). |
Q46903050 | Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). |
Q55071239 | Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. |
Q62583463 | TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes |
Q33566957 | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer |
Q52841976 | Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer. |
Q47321009 | Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer |
Q39178659 | Targeted intraoperative radiotherapy tumour bed boost during breast-conserving surgery after neoadjuvant chemotherapy |
Q48769304 | The 5-HTTLPR polymorphism modulates the influence on environmental stressors on peripartum depression symptoms. |
Q49817640 | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. |
Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
Q33769034 | The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial |
Q37210385 | The International Endometriosis Evaluation Program (IEEP Study) - A Systematic Study for Physicians, Researchers and Patients |
Q39147158 | The PI3K Pathway: Background and Treatment Approaches |
Q35781316 | The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients |
Q36917100 | The UGT1A6_19_GG genotype is a breast cancer risk factor |
Q36137764 | The contributions of breast density and common genetic variation to breast cancer risk |
Q51781776 | The era of centers: the influence of establishing specialized centers on patients' choice of hospital. |
Q28389045 | The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial |
Q36357800 | The integrative epigenomic-transcriptomic landscape of ER positive breast cancer |
Q57265642 | The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant |
Q64258248 | The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer |
Q35024008 | The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing |
Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
Q21195217 | The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer |
Q61814603 | Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry |
Q34129643 | Time and Resources Needed to Document Patients with Breast Cancer from Primary Diagnosis to Follow-up - Results of a Single-center Study |
Q52887281 | Tissue remodeling and nonendometrium-like menstrual cycling are hallmarks of peritoneal endometriosis lesions. |
Q36539580 | Touch Imprint Cytology and Stereotactically-Guided Core Needle Biopsy of Suspicious Breast Lesions: 15-Year Follow-up |
Q33432594 | Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial |
Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
Q62022868 | Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer |
Q47663023 | Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry |
Q44267362 | Treatment of endometrial carcinoma - evidence based criteria |
Q58797082 | Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing |
Q47322152 | Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy |
Q43215450 | Two naturally occurring variants of the serotonin receptor gene HTR3C are associated with nausea in pregnancy |
Q92994868 | Two truncating variants in FANCC and breast cancer risk |
Q45991085 | Ultrasound elastography of pulmonary lesions - a feasibility study. |
Q47110841 | Update Breast Cancer 2017 - Implementation of Novel Therapies |
Q52632717 | Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers. |
Q52632715 | Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. |
Q59335358 | Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer |
Q59335362 | Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer |
Q64102998 | Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer |
Q64102991 | Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice |
Q64273108 | Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel |
Q39046820 | Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment |
Q38884752 | Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network |
Q56968394 | Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians |
Q41570633 | Using automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound |
Q56342454 | Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility |
Q33847791 | Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer |
Q48096559 | Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients |
Q36917641 | Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills |
Q52850868 | Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). |
Q53050911 | [Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation]. |
Q53077783 | [Future of mammography-based imaging]. |
Q50449749 | [Pre-, peri- and postpartal depression]. |
Q54384993 | [Sebaceous breast carcinoma: report of a rare histological special subtype]. |
Q58587476 | [TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes] |
Q122925830 | p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study |
Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
Q56334023 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology |
Search more.